Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A Phase 1 study to evaluate the safety, tolerability, pharmacogenetics and pharmacodynamics of PF-06939999 (PRMT5 inhibitor)


General Information

Age Group




Protocol Number


Background Information

The purpose of this study is to learn about the effects of the study drug PF-06939999 and to find the best dose for treating your cancer.

Offered At

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

Eligibility Information

  • Participants must be 18 years of age or older
  • Histological or cytological diagnosis of a solid tumor that is advanced/metastatic, participants are intolerant to standard treatment or resistant to standard therapy
  • Participants must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, Section 10.11) that has not been previously irradiated
  • Adequate bone marrow, renal, and liver function
  • Additional eligibility in protocol

Ineligibility Information

  • Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth
  • Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Major surgery within 4 weeks prior to study entry.
  • Radiation therapy within 4 weeks prior to study entry.
  • Systemic anti-cancer therapy within 4 weeks prior to study entry (6 weeks for mitomycin C or nitrosoureas)
  • Participants with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness. HIV seropositive subjects who are healthy and low-risk for AIDS-related outcomes could be considered eligible
  • Additional exclusions in protocol

Additional information can be found at